Biomarkers /
NRAS
Back to Biomarkers List
Overview
NRAS (neuroblastoma RAS viral (v-ras) oncogene homolog) encodes for the GTPase NRas protein, one of three human RAS proteins. RAS proteins are small GTPases that are central mediators downstream of growth factor receptor signaling and therefore critical for cell proliferation, survival, and differentiation. NRAS is implicated in the pathogenesis of several cancers (for review see PMID: 17384584).
NRAS is altered in 2.90% of all cancers with melanoma, colorectal adenocarcinoma, leukemia, thyroid gland neoplasm, and non-small cell lung carcinoma having the greatest prevalence of alterations [3].
The most common alterations in NRAS are NRAS Mutation (3.80%), NRAS Mutation (germline) (3.80%), NRAS Mutation (somatic) (3.80%), NRAS Codon 61 Missense (2.33%), and NRAS Q61R (1.06%) [3].
Biomarker-Directed Therapies
NRAS is a predictive biomarker for use of cetuximab and panitumumab in patients.
Colorectal carcinoma has the most therapies with NRAS as a predictive biomarker.
Of the therapies with NRAS as a predictive biomarker, 2 are FDA-approved in at least one clinical setting and 2 have NCCN guidelines in at least one clinical setting.
Cetuximab +
Colorectal Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (FDA, NCCN, ASCO) |
|
Biomarker Criteria:
Sample must match one or more of the following:
KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS A146P, KRAS A146T, KRAS A146V, KRAS G12S, KRAS G12V, KRAS G13A, KRAS G13C, KRAS G13D, KRAS G13R, KRAS G13S, KRAS G13V, KRAS K117N, KRAS Q61H, KRAS Q61K, KRAS Q61L, KRAS Q61P, KRAS Q61R, NRAS G12A, NRAS G12C, NRAS G12D, NRAS G12S, NRAS G12V, NRAS Q61K, NRAS Q61R |
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (FDA, NCCN, MCG, ASCO) |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Theoretical Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) |
Panitumumab +
Colorectal Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (FDA, NCCN, ASCO) |
|
Biomarker Criteria:
Sample must match one or more of the following:
KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS A146P, KRAS A146T, KRAS A146V, KRAS G12S, KRAS G12V, KRAS G13A, KRAS G13C, KRAS G13D, KRAS G13R, KRAS G13S, KRAS G13V, KRAS K117N, KRAS Q61H, KRAS Q61K, KRAS Q61L, KRAS Q61P, KRAS Q61R, NRAS G12A, NRAS G12C, NRAS G12D, NRAS G12S, NRAS G12V, NRAS Q61K, NRAS Q61R |
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (FDA, NCCN, MCG, ASCO) |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Theoretical Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) |
Clinical Trials
NRAS status serves as an inclusion eligibility criteria in 74 clinical trials, of which 60 are open and 14 are closed. Of the trials that contain NRAS status as an inclusion criterion, 25 are phase 1 (19 open), 22 are phase 1/phase 2 (18 open), 25 are phase 2 (21 open), 1 is phase 3 (1 open), and 1 is phase 4 (1 open).
Trials with NRAS status in the inclusion eligibility criteria most commonly target malignant solid tumor, colorectal carcinoma, melanoma, non-small cell lung carcinoma, and acute myeloid leukemia [4].
The most frequent alterations to serve as inclusion eligibility criteria are NRAS Mutation, NRAS Q61E, NRAS Q61H, NRAS Q61K, and NRAS Q61L [4].
Trametinib, selumetinib, binimetinib, adavosertib, and dabrafenib are the most frequent therapies in trials with NRAS as an inclusion criteria [4].
Significance of NRAS in Diseases
Malignant Solid Tumor +
NRAS is mutated in 25.63% of malignant solid tumor patients [3].
NRAS is an inclusion criterion in 28 clinical trials for malignant solid tumor, of which 24 are open and 4 are closed. Of the trials that contain NRAS status and malignant solid tumor as inclusion criteria, 14 are phase 1 (10 open), 7 are phase 1/phase 2 (7 open), and 7 are phase 2 (7 open) [4].
Selumetinib, defactinib, and adavosertib are the most frequent therapies in malignant solid tumor trials with NRAS alterations as inclusion criteria [4].
Colorectal Carcinoma +
NRAS is mutated in 3.99% of colorectal carcinoma patients [3].
NRAS is an inclusion criterion in 14 clinical trials for colorectal carcinoma, of which 13 are open and 1 is closed. Of the trials that contain NRAS status and colorectal carcinoma as inclusion criteria, 8 are phase 1 (8 open), 4 are phase 1/phase 2 (4 open), and 2 are phase 2 (1 open) [4].
Trametinib, asn007, and gemcitabine are the most frequent therapies in colorectal carcinoma trials with NRAS alterations as inclusion criteria [4].
Melanoma +
NRAS is mutated in 23.41% of melanoma patients [3].
NRAS is an inclusion criterion in 13 clinical trials for melanoma, of which 8 are open and 5 are closed. Of the trials that contain NRAS status and melanoma as inclusion criteria, 6 are phase 1 (3 open), 4 are phase 1/phase 2 (2 open), 1 is phase 2 (1 open), 1 is phase 3 (1 open), and 1 is phase 4 (1 open) [4].
Asn007, cdx-3379, and erk1/2 inhibitor ly3214996 are the most frequent therapies in melanoma trials with NRAS alterations as inclusion criteria [4].
Non-Small Cell Lung Carcinoma +
NRAS is mutated in 1.14% of non-small cell lung carcinoma patients [3].
NRAS is an inclusion criterion in 11 clinical trials for non-small cell lung carcinoma, of which 11 are open and 0 are closed. Of the trials that contain NRAS status and non-small cell lung carcinoma as inclusion criteria, 5 are phase 1 (5 open), 3 are phase 1/phase 2 (3 open), and 3 are phase 2 (3 open) [4].
Selumetinib, akt inhibitor mk2206, and encorafenib are the most frequent therapies in non-small cell lung carcinoma trials with NRAS alterations as inclusion criteria [4].
Acute Myeloid Leukemia +
NRAS is mutated in 9.81% of acute myeloid leukemia patients [3].
NRAS is an inclusion criterion in 9 clinical trials for acute myeloid leukemia, of which 5 are open and 4 are closed. Of the trials that contain NRAS status and acute myeloid leukemia as inclusion criteria, 2 are phase 1 (1 open), 4 are phase 1/phase 2 (2 open), and 3 are phase 2 (2 open) [4].
Binimetinib, busulfan, and allogeneic hematopoietic stem cell transplantation are the most frequent therapies in acute myeloid leukemia trials with NRAS alterations as inclusion criteria [4].
Myelodysplastic Syndromes +
NRAS is mutated in 2.31% of myelodysplastic syndromes patients [3].
NRAS is an inclusion criterion in 7 clinical trials for myelodysplastic syndromes, of which 5 are open and 2 are closed. Of the trials that contain NRAS status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [4].
Allogeneic hematopoietic stem cell transplantation, busulfan, and fludarabine are the most frequent therapies in myelodysplastic syndromes trials with NRAS alterations as inclusion criteria [4].
Multiple Myeloma +
NRAS is an inclusion criterion in 6 clinical trials for multiple myeloma, of which 5 are open and 1 is closed. Of the trials that contain NRAS status and multiple myeloma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (2 open) [4].
Trametinib, erdafitinib, and dabrafenib are the most frequent therapies in multiple myeloma trials with NRAS alterations as inclusion criteria [4].
Chronic Myelomonocytic Leukemia +
NRAS is mutated in 18.67% of chronic myelomonocytic leukemia patients [3].
NRAS is an inclusion criterion in 5 clinical trials for chronic myelomonocytic leukemia, of which 4 are open and 1 is closed. Of the trials that contain NRAS status and chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [4].
Busulfan, fludarabine, and allogeneic cd56-positive cd3-negative natural killer cells are the most frequent therapies in chronic myelomonocytic leukemia trials with NRAS alterations as inclusion criteria [4].
Non-Hodgkin Lymphoma +
NRAS is mutated in 3.6% of non-hodgkin lymphoma patients [3].
NRAS is an inclusion criterion in 5 clinical trials for non-hodgkin lymphoma, of which 5 are open and 0 are closed. Of the trials that contain NRAS status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 4 are phase 2 (4 open) [4].
Ulixertinib, selumetinib, and antineoplastic immune cell are the most frequent therapies in non-hodgkin lymphoma trials with NRAS alterations as inclusion criteria [4].
Acute Lymphoblastic Leukemia +
NRAS is mutated in 12.45% of acute lymphoblastic leukemia patients [3].
NRAS is an inclusion criterion in 4 clinical trials for acute lymphoblastic leukemia, of which 4 are open and 0 are closed. Of the trials that contain NRAS status and acute lymphoblastic leukemia as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 2 are phase 2 (2 open) [4].
Antineoplastic immune cell, ect-001 expanded cord blood, and allogeneic hematopoietic stem cell transplantation are the most frequent therapies in acute lymphoblastic leukemia trials with NRAS alterations as inclusion criteria [4].
Glioma +
NRAS is mutated in 0.81% of glioma patients [3].
NRAS is an inclusion criterion in 4 clinical trials for glioma, of which 4 are open and 0 are closed. Of the trials that contain NRAS status and glioma as inclusion criteria, 4 are phase 1/phase 2 (4 open) [4].
Cobimetinib and trametinib are the most frequent therapies in glioma trials with NRAS alterations as inclusion criteria [4].
Ovarian Carcinoma +
NRAS is mutated in 6.82% of ovarian carcinoma patients [3].
NRAS is an inclusion criterion in 3 clinical trials for ovarian carcinoma, of which 3 are open and 0 are closed. Of the trials that contain NRAS status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (2 open) [4].
Extended release flucytosine, sra737, and vistusertib are the most frequent therapies in ovarian carcinoma trials with NRAS alterations as inclusion criteria [4].
Colorectal Adenocarcinoma +
NRAS is mutated in 4.48% of colorectal adenocarcinoma patients [3].
NRAS is an inclusion criterion in 3 clinical trials for colorectal adenocarcinoma, of which 3 are open and 0 are closed. Of the trials that contain NRAS status and colorectal adenocarcinoma as inclusion criteria, 3 are phase 2 (3 open) [4].
Pancreatic Carcinoma +
NRAS is mutated in 0.83% of pancreatic carcinoma patients [3].
NRAS is an inclusion criterion in 3 clinical trials for pancreatic carcinoma, of which 3 are open and 0 are closed. Of the trials that contain NRAS status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (2 open) [4].
Extended release flucytosine, valproic acid, and vistusertib are the most frequent therapies in pancreatic carcinoma trials with NRAS alterations as inclusion criteria [4].
Neurofibromatosis Type 1 +
NRAS is an inclusion criterion in 3 clinical trials for neurofibromatosis type 1, of which 3 are open and 0 are closed. Of the trials that contain NRAS status and neurofibromatosis type 1 as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 1 is phase 2 (1 open) [4].
Azacitidine and trametinib are the most frequent therapies in neurofibromatosis type 1 trials with NRAS alterations as inclusion criteria [4].
Pancreatic Ductal Adenocarcinoma +
NRAS is an inclusion criterion in 3 clinical trials for pancreatic ductal adenocarcinoma, of which 3 are open and 0 are closed. Of the trials that contain NRAS status and pancreatic ductal adenocarcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [4].
Asn007, erk1/2 inhibitor ly3214996, and abemaciclib are the most frequent therapies in pancreatic ductal adenocarcinoma trials with NRAS alterations as inclusion criteria [4].
Head And Neck Squamous Cell Carcinoma +
NRAS is mutated in 1.34% of head and neck squamous cell carcinoma patients [3].
NRAS is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NRAS status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].
Ko-947 and sra737 are the most frequent therapies in head and neck squamous cell carcinoma trials with NRAS alterations as inclusion criteria [4].
Lymphoma +
NRAS is mutated in 0.89% of lymphoma patients [3].
NRAS is an inclusion criterion in 2 clinical trials for lymphoma, of which 2 are open and 0 are closed. Of the trials that contain NRAS status and lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].
Azd4547, erdafitinib, and vismodegib are the most frequent therapies in lymphoma trials with NRAS alterations as inclusion criteria [4].
Small Cell Lung Carcinoma +
NRAS is mutated in 0.85% of small cell lung carcinoma patients [3].
NRAS is an inclusion criterion in 2 clinical trials for small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NRAS status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].
Akt inhibitor mk2206, auranofin, and erlotinib are the most frequent therapies in small cell lung carcinoma trials with NRAS alterations as inclusion criteria [4].
Squamous Cell Lung Carcinoma +
NRAS is mutated in 1.05% of squamous cell lung carcinoma patients [3].
NRAS is an inclusion criterion in 2 clinical trials for squamous cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NRAS status and squamous cell lung carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [4].
Auranofin, vistusertib, and selumetinib are the most frequent therapies in squamous cell lung carcinoma trials with NRAS alterations as inclusion criteria [4].
Neuroblastoma +
NRAS is mutated in 0.93% of neuroblastoma patients [3].
NRAS is an inclusion criterion in 2 clinical trials for neuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain NRAS status and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].
Cobimetinib is the most frequent therapy in neuroblastoma trials with NRAS alterations as inclusion criteria [4].
Breast Carcinoma +
NRAS is mutated in 0.55% of breast carcinoma patients [3].
NRAS is an inclusion criterion in 2 clinical trials for breast carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NRAS status and breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].
Extended release flucytosine, vistusertib, and selumetinib are the most frequent therapies in breast carcinoma trials with NRAS alterations as inclusion criteria [4].
Poorly Differentiated Thyroid Gland Carcinoma +
NRAS is mutated in 31.03% of poorly differentiated thyroid gland carcinoma patients [3].
NRAS is an inclusion criterion in 1 clinical trial for poorly differentiated thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and poorly differentiated thyroid gland carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Thyroid stimulating hormone [epc], dabrafenib, and trametinib are the most frequent therapies in poorly differentiated thyroid gland carcinoma trials with NRAS alterations as inclusion criteria [4].
Thyroid Gland Adenocarcinoma +
NRAS is mutated in 30.89% of thyroid gland adenocarcinoma patients [3].
NRAS is an inclusion criterion in 1 clinical trial for thyroid gland adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and thyroid gland adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Iodine i-124 fiau, iodine i-131, and trametinib are the most frequent therapies in thyroid gland adenocarcinoma trials with NRAS alterations as inclusion criteria [4].
Thyroid Gland Follicular Carcinoma +
NRAS is mutated in 16.13% of thyroid gland follicular carcinoma patients [3].
NRAS is an inclusion criterion in 1 clinical trial for thyroid gland follicular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and thyroid gland follicular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Thyroid stimulating hormone [epc], dabrafenib, and trametinib are the most frequent therapies in thyroid gland follicular carcinoma trials with NRAS alterations as inclusion criteria [4].
Thyroid Gland Carcinoma +
NRAS is mutated in 10.05% of thyroid gland carcinoma patients [3].
NRAS is an inclusion criterion in 1 clinical trial for thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Vistusertib and selumetinib are the most frequent therapies in thyroid gland carcinoma trials with NRAS alterations as inclusion criteria [4].
Rhabdomyosarcoma +
NRAS is mutated in 9.48% of rhabdomyosarcoma patients [3].
NRAS is an inclusion criterion in 1 clinical trial for rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and rhabdomyosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Cobimetinib is the most frequent therapy in rhabdomyosarcoma trials with NRAS alterations as inclusion criteria [4].
Thyroid Gland Papillary Carcinoma +
NRAS is mutated in 8.48% of thyroid gland papillary carcinoma patients [3].
NRAS is an inclusion criterion in 1 clinical trial for thyroid gland papillary carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and thyroid gland papillary carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Thyroid stimulating hormone [epc], dabrafenib, and trametinib are the most frequent therapies in thyroid gland papillary carcinoma trials with NRAS alterations as inclusion criteria [4].
Histiocytic And Dendritic Cell Neoplasm +
NRAS is mutated in 6.1% of histiocytic and dendritic cell neoplasm patients [3].
NRAS is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].
Selumetinib is the most frequent therapy in histiocytic and dendritic cell neoplasm trials with NRAS alterations as inclusion criteria [4].
Colon Carcinoma +
NRAS is mutated in 4.67% of colon carcinoma patients [3].
NRAS is an inclusion criterion in 1 clinical trial for colon carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and colon carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Valproic acid and neratinib are the most frequent therapies in colon carcinoma trials with NRAS alterations as inclusion criteria [4].
Malignant Peripheral Nerve Sheath Tumor +
NRAS is mutated in 3.33% of malignant peripheral nerve sheath tumor patients [3].
NRAS is an inclusion criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Cobimetinib is the most frequent therapy in malignant peripheral nerve sheath tumor trials with NRAS alterations as inclusion criteria [4].
Endometrial Carcinoma +
NRAS is mutated in 2.67% of endometrial carcinoma patients [3].
NRAS is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Vistusertib and selumetinib are the most frequent therapies in endometrial carcinoma trials with NRAS alterations as inclusion criteria [4].
Soft Tissue Sarcoma +
NRAS is mutated in 1.62% of soft tissue sarcoma patients [3].
NRAS is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Cobimetinib is the most frequent therapy in soft tissue sarcoma trials with NRAS alterations as inclusion criteria [4].
Sarcoma +
NRAS is mutated in 1.63% of sarcoma patients [3].
NRAS is an inclusion criterion in 1 clinical trial for sarcoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and sarcoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Extended release flucytosine and vocimagene amiretrorepvec are the most frequent therapies in sarcoma trials with NRAS alterations as inclusion criteria [4].
Chronic Myeloid Leukemia +
NRAS is mutated in 1.47% of chronic myeloid leukemia patients [3].
NRAS is an inclusion criterion in 1 clinical trial for chronic myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and chronic myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Allogeneic cd56-positive cd3-negative natural killer cells, interleukin-2, and allogeneic hematopoietic stem cell transplantation are the most frequent therapies in chronic myeloid leukemia trials with NRAS alterations as inclusion criteria [4].
Bladder Carcinoma +
NRAS is mutated in 1.57% of bladder carcinoma patients [3].
NRAS is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and bladder carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Extended release flucytosine and vocimagene amiretrorepvec are the most frequent therapies in bladder carcinoma trials with NRAS alterations as inclusion criteria [4].
Head And Neck Carcinoma +
NRAS is mutated in 1.38% of head and neck carcinoma patients [3].
NRAS is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Extended release flucytosine and vocimagene amiretrorepvec are the most frequent therapies in head and neck carcinoma trials with NRAS alterations as inclusion criteria [4].
Thymic Carcinoma +
NRAS is mutated in 1.33% of thymic carcinoma patients [3].
NRAS is an inclusion criterion in 1 clinical trial for thymic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and thymic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Akt inhibitor mk2206, erlotinib, and lapatinib are the most frequent therapies in thymic carcinoma trials with NRAS alterations as inclusion criteria [4].
Adenocarcinoma Of The Gastroesophageal Junction +
NRAS is mutated in 1.31% of adenocarcinoma of the gastroesophageal junction patients [3].
NRAS is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 0 are open and 1 is closed. Of the trial that contains NRAS status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (0 open) [4].
Docetaxel and selumetinib are the most frequent therapies in adenocarcinoma of the gastroesophageal junction trials with NRAS alterations as inclusion criteria [4].
Glioblastoma +
NRAS is mutated in 0.86% of glioblastoma patients [3].
NRAS is an inclusion criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and glioblastoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Extended release flucytosine and vocimagene amiretrorepvec are the most frequent therapies in glioblastoma trials with NRAS alterations as inclusion criteria [4].
Diffuse Large B-Cell Lymphoma +
NRAS is mutated in 0.5% of diffuse large B-cell lymphoma patients [3].
NRAS is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Antineoplastic immune cell, allogeneic hematopoietic stem cell transplantation, and autologous hematopoietic stem cell transplatation are the most frequent therapies in diffuse large B-cell lymphoma trials with NRAS alterations as inclusion criteria [4].
Anaplastic Astrocytoma +
NRAS is mutated in 0.33% of anaplastic astrocytoma patients [3].
NRAS is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Extended release flucytosine and vocimagene amiretrorepvec are the most frequent therapies in anaplastic astrocytoma trials with NRAS alterations as inclusion criteria [4].
Hepatocellular Carcinoma +
NRAS is mutated in 0.31% of hepatocellular carcinoma patients [3].
NRAS is an inclusion criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and hepatocellular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Prostate Carcinoma +
NRAS is mutated in 0.32% of prostate carcinoma patients [3].
NRAS is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and prostate carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Sra737 is the most frequent therapy in prostate carcinoma trials with NRAS alterations as inclusion criteria [4].
Renal Cell Carcinoma +
NRAS is mutated in 0.16% of renal cell carcinoma patients [3].
NRAS is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and renal cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Vistusertib and selumetinib are the most frequent therapies in renal cell carcinoma trials with NRAS alterations as inclusion criteria [4].
Double-Hit Lymphoma +
NRAS is an inclusion criterion in 1 clinical trial for double-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and double-hit lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Antineoplastic immune cell, allogeneic hematopoietic stem cell transplantation, and autologous hematopoietic stem cell transplatation are the most frequent therapies in double-hit lymphoma trials with NRAS alterations as inclusion criteria [4].
Gastric Adenocarcinoma +
NRAS is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains NRAS status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].
Docetaxel and selumetinib are the most frequent therapies in gastric adenocarcinoma trials with NRAS alterations as inclusion criteria [4].
Juvenile Myelomonocytic Leukemia +
NRAS is an inclusion criterion in 1 clinical trial for juvenile myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and juvenile myelomonocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].
Azacitidine is the most frequent therapy in juvenile myelomonocytic leukemia trials with NRAS alterations as inclusion criteria [4].
Mantle Cell Lymphoma +
NRAS is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and mantle cell lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Antineoplastic immune cell, allogeneic hematopoietic stem cell transplantation, and autologous hematopoietic stem cell transplatation are the most frequent therapies in mantle cell lymphoma trials with NRAS alterations as inclusion criteria [4].
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable +
NRAS is an inclusion criterion in 1 clinical trial for myelodysplastic/myeloproliferative neoplasm, unclassifiable, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and myelodysplastic/myeloproliferative neoplasm, unclassifiable as inclusion criteria, 1 is phase 1 (1 open) [4].
Busulfan, fludarabine, and venetoclax are the most frequent therapies in myelodysplastic/myeloproliferative neoplasm, unclassifiable trials with NRAS alterations as inclusion criteria [4].
Peripheral T-Cell Lymphoma +
NRAS is an inclusion criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Antineoplastic immune cell, allogeneic hematopoietic stem cell transplantation, and autologous hematopoietic stem cell transplatation are the most frequent therapies in peripheral T-cell lymphoma trials with NRAS alterations as inclusion criteria [4].
Refractory Anemia With Excess Blasts +
NRAS is an inclusion criterion in 1 clinical trial for refractory anemia with excess blasts, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and refractory anemia with excess blasts as inclusion criteria, 1 is phase 2 (1 open) [4].
Azacitidine is the most frequent therapy in refractory anemia with excess blasts trials with NRAS alterations as inclusion criteria [4].
Refractory Anemia With Excess Blasts-2 +
NRAS is an inclusion criterion in 1 clinical trial for refractory anemia with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and refractory anemia with excess blasts-2 as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Binimetinib is the most frequent therapy in refractory anemia with excess blasts-2 trials with NRAS alterations as inclusion criteria [4].
Rhabdoid Tumor +
NRAS is an inclusion criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and rhabdoid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Cobimetinib is the most frequent therapy in rhabdoid tumor trials with NRAS alterations as inclusion criteria [4].
Schwannoma +
NRAS is an inclusion criterion in 1 clinical trial for schwannoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and schwannoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Cobimetinib is the most frequent therapy in schwannoma trials with NRAS alterations as inclusion criteria [4].
Secondary Acute Myeloid Leukemia +
NRAS is an inclusion criterion in 1 clinical trial for secondary acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and secondary acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].
Ect-001 expanded cord blood is the most frequent therapy in secondary acute myeloid leukemia trials with NRAS alterations as inclusion criteria [4].
Therapy-Related Acute Myeloid Leukemia +
NRAS is an inclusion criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].
Ect-001 expanded cord blood is the most frequent therapy in therapy-related acute myeloid leukemia trials with NRAS alterations as inclusion criteria [4].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20170629. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
